Novavax Expands Leadership with Several Key Management Promotions
November 12 2018 - 4:05PM
Novavax, Inc. (Nasdaq: NVAX) today announced several management
promotions.
“We are pleased to announce several key
management promotions to further support the advancement of our
company and its lead clinical programs into commercial stage," said
Stanley Erck, President and Chief Executive Officer of Novavax,
Inc. “These individuals have worked closely with our senior
leadership team and have made significant contributions to ensure
we drive our ResVax and NanoFlu programs towards licensure. We are
extremely fortunate to have a seasoned in-house team that continues
to deliver results.”
The following individuals have been
promoted:
- Jody Lichaa to Senior Vice President, Quality Assurance
- Brian Rosen to Senior Vice President, Commercial Strategy
- Kathleen Callahan to Vice President, Regulatory Affairs,
CMC
- Susan Hensley to Vice President, Regulatory Operations
- Brian Webb to Vice President, Manufacturing
Ms. Lichaa joined Novavax in October 2011 as
Director, Quality Assurance. She was named Executive Director,
Quality Assurance in August 2013 and then named Vice President,
Quality Assurance in October 2015. Her role has recently expanded
to include quality assurance validation, clinical quality
assurance, and quality assurance globally. Ms. Lichaa will continue
to serve as the strategic leader and operational manager to direct,
oversee, and manage all quality assurance activities. She has more
than 20 years of experience in quality, primarily in vaccine
development. Prior to joining Novavax, Ms. Lichaa was most recently
the Senior Director, Quality for PharmAthene, where she managed
global quality assurance and quality control activities. She
previously held positions of increasing responsibility at Shire and
Baxter. Ms. Lichaa received her Bachelor of Science degree in
Toxicology from Northeastern University.
Mr. Rosen joined Novavax in 2015 as Vice
President, Market Access and Policy and was named Vice President,
Commercial Strategy in June 2018 with responsibility for leading
commercial strategy efforts. He came to Novavax with more than 20
years of industry, legal and patient advocacy experience, the vast
majority engaged in government affairs, advocacy, reimbursement and
policy work. Prior to Novavax, Mr. Rosen was most recently the
Chief Policy, Advocacy and Patient Access Officer for the Leukemia
& Lymphoma Society and, prior to that, developed and ran the
Government Affairs, Policy and Alliance Development functions for
MedImmune. Mr. Rosen currently serves as Chair of the Board of
Directors of MdBio Foundation. Mr. Rosen received his Bachelor of
Arts degree in History and Psychology from Tufts University and his
Juris Doctorate from Hofstra University School of Law.
Ms. Callahan joined Novavax in July 2011 as
Director, Regulatory Affairs and was named Executive Director,
Regulatory Affairs in April 2017. She has led the efforts to reach
agreements with the U.S. and European regulatory agencies for CMC
requirements for marketing applications and continues to prepare
the CMC sections of our marketing applications. Ms. Callahan has
more than 25 years of experience in vaccine development, with 16
years in Regulatory Affairs. She previously held positions of
increasing responsibility at Baxter, GlaxoSmithKline, and
PharmAthene. She received her Bachelor of Science degree in Biology
from Mount Saint Mary’s College and a Master of Science degree in
Biomedical Science (Biotechnology/Molecular Biology) from Hood
College.
Ms. Hensley joined Novavax in May 2014 as
Director, Regulatory Operations and was named Executive Director,
Regulatory Operations in April 2017. She has more than 24 years of
experience in regulatory information and submissions management,
policy enforcement, and team performance. Prior to joining Novavax,
Ms. Hensley led the successful compilation and filing of two
biologics license applications as the Head of Regulatory Operations
at Human Genome Sciences. She received her Bachelor of Arts degree
at University of Maryland Baltimore County and her Master of
Science degree in Clinical Social Work from University of Maryland,
Baltimore. She is currently working on a Master of Science Degree
of Regulatory Science at Johns Hopkins University.
Mr. Webb joined Novavax in May 2014 as Senior
Director, Manufacturing and was named Executive Director,
Manufacturing in December 2016. His role recently expanded to
include Supply Chain with end-to-end accountability for clinical
and commercial vaccine production. Prior to joining Novavax, Mr.
Webb held numerous operational leadership roles at GlaxoSmithKline
and Human Genome Sciences where he had the opportunity to take
multiple products from early clinical stage through licensure and
launch. He received his Bachelor of Science degree in Biology from
Salisbury University and his Master of Science degree in
Biotechnology from Johns Hopkins University.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a late-stage
biotechnology company that drives improved health globally through
the discovery, development, and commercialization of innovative
vaccines to prevent serious infectious diseases. ResVax™, its RSV
vaccine for infants via maternal immunization, is the only vaccine
in a Phase 3 clinical program and is designed to prevent the second
leading cause of death in children under one year of age worldwide.
Novavax is also advancing NanoFlu™, its quadrivalent influenza
nanoparticle vaccine, to address key factors that can lead to the
poor effectiveness of currently approved flu vaccines. Novavax is a
leading innovator of recombinant vaccines; its proprietary
recombinant technology platform combines the power and speed of
genetic engineering to efficiently produce a new class of highly
immunogenic nanoparticles addressing urgent global health
needs.
For more information, visit
www.novavax.com and connect with us on Twitter and
LinkedIn.
Forward-Looking Statements
Statements herein relating to the future of
Novavax and the ongoing development of its vaccine and adjuvant
products are forward-looking statements. Novavax cautions that
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include those identified under the
heading “Risk Factors” in the Novavax Annual Report on Form 10-K
for the year ended December 31, 2017 and the Quarterly Report on
Form 10-Q for the period ended September 30, 2018 as filed with the
Securities and Exchange Commission (SEC). We caution investors not
to place considerable reliance on the forward-looking statements
contained in this press release. You are encouraged to read our
filings with the SEC, available at sec.gov, for a discussion of
these and other risks and uncertainties. The forward-looking
statements in this press release speak only as of the date of this
document, and we undertake no obligation to update or revise any of
the statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties. Contacts:
InvestorsNovavax, Inc.Erika Trahanir@novavax.com240-268-2000
Westwicke PartnersJohn
Woolfordjohn.woolford@westwicke.com 443-213-0506
MediaSam BrownMike Beyermikebeyer@sambrown.com312-961-2502
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024